The pharmaceutical giants Biontech and Pfizer are almost ready: the joint vaccine against the omicron variant should be available in March – the companies have now started a clinical study on safety, effectiveness and tolerability.
That reports IMAGE. The study should therefore include up to 1420 test persons.
Biontech CEO Ugur Sahin explained: “The study is part of our scientific approach to develop a variant-based vaccine that offers protection against omicron similar to that we have observed with previous variants, but at the same time lasts longer.”
Vaccines still offer a high level of protection against severe courses from omicron.
Also read: Biontech announces adapted vaccine against Omicron for March
The Mainz-based pharmaceutical company and its US partner announced only around two weeks ago that they had already started production of a corona vaccine adapted to the omicron variant for later commercial use.
Biontech had stated that the two companies are “ready to supply the market by March, once regulatory approvals have been received.”